A substrate based skin contact material formed from a hydrocolloid having a silicone based component extending over regions of the substrate surface. The adhesive is formed non-continuously over the substrate to provide areas devoid of adhesive to allow appreciable moisture transfer between the skin and substrate and improve the skin friendliness of the material during use and allow convenient removal with avoidance of skin irritation.

A substrate based skin contact material formed from a hydrocolloid having a silicone based component extending over regions of the substrate surface. The adhesive is formed non-continuously over the substrate to provide areas devoid of adhesive to allow appreciable moisture transfer between the skin and substrate and improve the skin friendliness of the material during use and allow convenient removal with avoidance of skin irritation.

An adhesive wafer for an ostomy device, the wafer comprising a skin-facing adhesive layer, a backing layer on a part of the non-skin-facing side of the adhesive layer, and a hole for accommodating a stoma. On the central portion of the wafer is located a release layer being configured to release a neutralizer. The release layer is in direct contact with the adhesive layer. The neutralizer is capable of neutralizing or at least minimizing the level of skin or adhesive aggressiveness of the output.

An adhesive wafer for an ostomy device, the wafer comprising a skin-facing adhesive layer, a backing layer on a part of the non-skin-facing side of the adhesive layer, and a hole for accommodating a stoma. On the central portion of the wafer is located a release layer being configured to release a neutralizer. The release layer is in direct contact with the adhesive layer. The neutralizer is capable of neutralizing or at least minimizing the level of skin or adhesive aggressiveness of the output.

The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.

The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.

The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.

The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the tissue-active monomers, including monomers comprising macromolecules, provide abroad set of material choices for synthetic tissue barriers. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.

The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the tissue-active monomers, including monomers comprising macromolecules, provide abroad set of material choices for synthetic tissue barriers. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.

The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the tissue-active monomers, including monomers comprising macromolecules, provide abroad set of material choices for synthetic tissue barriers. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.